GNI Group (TSE: 2160), a biopharma company listed on the Tokyo Stock Exchange's Growth market, said on October 7, 2026 that it has been selected as a TOPIX constituent. The company expects its shares to be included in the index from October 30, 2026.
What the reform changes
GNI said the index is calculated by JPX Research Institute. It described the October 2026 review as the first regular reshuffle under the second stage of the TOPIX overhaul. In the company's account, the old method of choosing constituents was revised. Regular reshuffles now cover all three TSE market segments, Prime, Standard and Growth, using criteria such as liquidity and free-float market capitalisation.
The announcement is the company's own. The notice does not set out the specific criteria values GNI met, and it carries no separate confirmation from the index provider or the exchange.
What GNI expects
The company listed three expected benefits. ETFs and index funds that track TOPIX would hold its shares, which GNI hopes will diversify and stabilise its shareholder base. A wider range of domestic and overseas institutional investors may take it up as an investment and research target. The company also expects greater visibility in capital markets. These are management's expectations, not outcomes.
The company behind the listing
Chief executive Ying Luo said the group completed its acquisition of Ayumi Pharmaceutical in July 2026. Luo said that gave GNI a long-sought sales base in Japan. GNI describes itself as having operations and research bases in Japan, China, the US and Australia. Its lead development product is F351, a candidate treatment for liver fibrosis caused by chronic hepatitis B.